

## **viDA Therapeutics Inc. Appoints Orphan Product Regulatory Executive to Board of Directors**

Vancouver, British Columbia, Canada, August 31, 2016 -- viDA Therapeutics, Inc. (viDA) announced today that Dr. Marlene Haffner has been appointed to its Board of Directors.

Founder of Haffner Associates, LLC in 2009, Dr. Marlene Haffner was the Director of the Office of Orphan Products Development at the Food and Drug Administration (FDA) for 20+ years. During her tenure in that program, it became *THE* orphan products program in the world. In addition to assisting in the development of more than 300 products in the US, she is credited with assisting in the development of programs in Japan, the European Union, Australia, and beyond.

“I look forward to working the Board and Management of viDA and to support the company in its realization of its mission and objectives for its lead product VTI-1002.” noted Dr. Haffner “I hope that my experience and perspectives in the orphan drug development space can contribute to ensuring the rapid and successful development of this exciting program.”

“Marlene joining the Board and bringing her expertise to our technology will provide viDA with development and regulatory insights that will advance not only our lead orphan product candidate, VTI-1002 for the treatment of Discoid Lupus Erythematosus, an orphan autoimmune skin disorder, but also other therapeutic opportunities within our portfolio” said Mr. Alistair Duncan, President & CEO.

Dr. Robert Ryan, Chair of the viDA Board commented “Having worked with Marlene previously, and knowing her extensive experience in orphan product development Marlene will bring significant value and contributions to our Board as we move forward and make viDA a significant success.”

Trained as an internist and hematologist, Marlene graduated from the George Washington University School of Medicine and did further training at the Columbia University School of Medicine and the Albert Einstein College of Medicine, in New York City. She received her Masters of Public Health from the Johns Hopkins Bloomberg School of Public Health in Baltimore. Following her tenure at FDA and prior to forming Haffner Associates, Marlene served as Executive Director, Global Regulatory Intelligence and Policy for two years at Amgen, the largest biotech company in the world

### **About viDA and VTI-1002**

viDA Therapeutics, Inc. (viDA), a Vancouver, Canada based privately held biotechnology company, is focused on developing first-in-class therapies for treating autoimmune and chronic inflammatory diseases with high unmet need, including orphan products. The lead product candidate, VTI-1002, is in a topical formulation for the treatment of Discoid Lupus Erythematosus, an orphan chronic inflammatory autoimmune skin disorder. This disease is a severe chronic dermatological disease affecting women five times more than men. It can have a significant impact on quality of life due to severe facial disfigurement and scars. For additional information about viDA, please visit [www.vidatherapeutics.com](http://www.vidatherapeutics.com).

#### **Media Contact:**

Alistair Duncan, B.Sc., C.A.

President & CEO

Phone: (604)762-4789

[aduncan@vidatherapeutics.com](mailto:aduncan@vidatherapeutics.com)